Massivtransfusion – logistische und therapeutische Aspekte

1. Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) (2016) Überarbeitete S3-Leitlinie „Polytrauma / Schwerverletzten-Behandlung“ 012-019. Erreichbar unter: http://www.awmf.org/leitlinien/detail/ll/012-019.html. Zugriff am: 12.02.2017
2. ASA (American Society of Anesthesiologists) (2015) Practice guidelines for perioperative blood management: an updated report by the american society of anesthesiologists task force on perioperative blood management*. Anesthesiology 122:241-275
3. Boffard KD, Choong PIT, Kluger Y et al. (2009) The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. Transfusion 49:240S-247S
4. Brooke M, Yeung L, Miraflor E et al. (2016) Lactate predicts massive transfusion in hemodynamically normal patients. J Surg Res 204:139-144
5. Bundesärztekammer (BÄK, German Medical Association), (2014) Querschnittsleitlinien der BÄK zur Therapie mit Blutkomponenten und Plasmaderivaten. 4. überarbeitete und aktualisierte Auflage 2014. Erreichbar unter: http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/QLL_Haemotherapie_2014.pdf. Zugriff am: 09. Dec 2015
6. Funk M, Heiden M, Volz-Zang C (2017) Hämovigilanz-Bericht des Paul-Ehrlich-Institutes 2015. Auswertung der Meldungen von schweren Reaktionen und Zwischenfällen nach §63i AMG. Erreichbar unter: http://www.pei.de/DE/arzneimittelsicherheit-vigilanz/haemovigilanz/haemovigilanzberichte/haemovigilanzberichte-node.html. Zugriff am: 02. Jul 2017
7. Gonzalez E, Moore EE, Moore HB et al. (2016) Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg 263:1051-1059
8. Gustafson ML, Hollosi S, Chumbe JT et al. (2015) The effect of ethanol on lactate and base deficit as predictors of morbidity and mortality in trauma. Am J Emerg Med 33:607-613
9. Haas T, Fries D, Tanaka KA et al. (2015) Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: is there any evidence? Br J Anaesth 114:217-224
10. Hess JR, Holcomb JB (2015) Resuscitating PROPPRly. Transfusion 55:1362-1364
11. Hodgetts TJ, Mahoney PF, Russell MQ et al. (2006) ABC to <C>ABC: redefining the military trauma paradigm. Emerg Med J 23:745-746
12. Holcomb JB, Donathan DP, Cotton BA et al. (2015) Prehospital Transfusion of Plasma and Red Blood Cells in Trauma Patients. Prehosp Emerg Care 19:1-9
13. Holcomb JB, Tilley BC, Baraniuk S et al. (2015) Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313:471-482
14. Innerhofer P, Fries D, Mittermayr M et al. (2017) Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol
15. Jenkins DH, Rappold JF, Badloe JF et al. (2014) Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps. Shock 41 Suppl 1:3-12
16. Klein AA, Arnold P, Bingham RM et al. (2016) AAGBI guidelines: the use of blood components and their alternatives 2016. Anaesthesia 71:829-842
17. Koscielny J, Beyer-Westendorf J, Von Heymann C et al. (2012) [Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]. Hamostaseologie 32:287-293
18. Koscielny J, Von Tempelhoff GF, Ziemer S et al. (2004) A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 10:155-166
19. Kozek-Langenecker SA, Ahmed AB, Afshari A et al. (2017) Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 34:332-395
20. Lance MD, Ninivaggi M, Schols SE et al. (2012) Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 103:25-34
21. Levy JH, Grottke O, Fries D et al. (2017) Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. Anesth Analg 124:1268-1276
22. Lier H, Krep H, Schroeder S et al. (2008) Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 65:951-960

23. Lier H, Vorweg M, Hanke A et al. (2013) Thromboelastometry guided therapy of severe bleeding. Essener Runde algorithm. Hamostaseologie 33:51-61

24. Meybohm P, Choorapoikayil S, Wessels A et al. (2016) Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore) 95:e4490

25. Morrison CA, Carrick MM, Norman MA et al. (2011) Hypotensive resuscitation strategy reduces transfusion requirements and severe postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized controlled trial. J Trauma 70:652-663

26. Pierce A, Pittet JF (2014) Practical understanding of hemostasis and approach to the bleeding patient in the OR. Adv Anesth 32:1-21

27. Ponschab M, Schochl H, Gabriel C et al. (2015) Haemostatic profile of reconstituted blood in a proposed 1:1:1 ratio of packed red blood cells, platelet concentrate and four different plasma preparations. Anaesthesia 70:528-536

28. Rahbar E, Fox EE, Del Junco DJ et al. (2013) Early resuscitation intensity as a surrogate for bleeding severity and early mortality in the PROMMTT study. J Trauma Acute Care Surg 75:S16-23

29. Rossaint R, Bouillon B, Cerny V et al. (2016) The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 20:100

30. Savage SA, Zarzaur BL, Croce MA et al. (2013) Redefining massive transfusion when every second counts. J Trauma Acute Care Surg 74:396-400; discussion 400-392

31. Schlimp CJ, Ponschab M, Voelckel W et al. (2016) Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: a retrospective study. Scand J Trauma Resusc Emerg Med 24:29

32. Schochl H, Voelckel W, Maegele M et al. (2014) Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: A 7-day observational study of trauma patients. Critical Care:R147

33. Solheim B, Hellstern P (2010) Pathogen Inactivation of Plasma and Cryoprecipitate. In: AuBuchon J, Prowse C (eds) 5. Pathogen Inactivation: The Penultimale Paradigm Shift. AABB Press, Bethesda, MO, p 69-98

34. Spahn DR, Bouillon B, Cerny V et al. (2013) Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 17:R76

35. Spinella PC, Reddy HL, Jaffe JS et al. (2012) Fresh whole blood use for hemorrhagic shock: preserving benefit while avoiding complications. Anesth Analg 115:751-758

36. Stein P, Kaserer A, Spahn GH et al. (2017) Point-of-Care Coagulation Monitoring in Trauma Patients. Semin Thromb Hemost

37. Stein P, Kaserer A, Sprengel K et al. (2017) Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia

38. Tachon G, Harrois A, Tanaka S et al. (2014) Microcirculatory alterations in traumatic hemorrhagic shock. Crit Care Med 42:1433-1441

39. Tonglet ML (2016) Early Prediction of Ongoing Hemorrhage in Severe Trauma: Presentation of the Existing Scoring Systems. Arch Trauma Res 5:e33377

40. Truhlar A, Deakin CD, Soar J et al. (2015) European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation 95:148-201

41. Watson JJ, Pati S, Schreiber MA (2016) Plasma Transfusion: History, Current Realities, and Novel Improvements. Shock 46:468-479

42. Wirtz MR, Baumann HM, Klinkspoor JH et al. (2017) Viscoelastic Testing in Trauma. Semin Thromb Hemost 43:375-385

Die Rolle der Blutgruppen bei der Versorgungssicherung mit Blutkonserven

1. Wagner FF et al: Frequencies oft he blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany, Infusionsther Transfusionsmed 1995; 22: 285-290
2. Metaxas-Bühler M: Blutgruppen und Transfusion. Books on Demand (Schweiz) 2002.
3. Eckstein R und Zimmermann R: Immunhämatologie und klinische Transfusionsmedizin, 6. Auflage 2010, Urban und Fischer (München)
4. Bericht nach §21 TFG, www.pei.de
5. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Herausgegeben von der Bundesärztekammer auf Empfehlung ihres Wissenschaftlichen Beirates. 4. Auflage 2014, Deutscher Ärzteverlag (Köln)
6. Shander A et al: Patient blood management in Europe. Br J Anaesth (2012) 109 (1): 55-68.
7. Gombotz H und Hoffmann A: Patient Blood Management. Anaesthesist 2013; 62: 519-527
8. Meybohm P et al: Blutsparende Therapie der Anämie. Deutsches Ärzteblatt 2015; 112 (14): 626-628
9. Seifried E at al: How much blood is needed? Vox Sanguinis 2011; 100: 10-21.
10. Greinacher A et al: Demographic changes: The impact for safe blood supply. Transfus Med Hemother 2010; 37: 141-148.
11. Yazer MH et al: Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study. Transfusion 2016; 56: 1965-1973.
12. Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie). Aufgestellt gemäß §§ 12a und 18 Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut. Gesamtnovelle 2017, www.baek.de.
13. S3 - Leitlinie Polytrauma / Schwerverletzten-Behandlung, Stand 07/2016. Deutsche Gesellschaft für Unfallchirurgie (federführend).
14. Weißbuch Schwerverletzten-Versorgung der Deutschen Gesellschaft für Unfallchirurgie. 2. Erweiterte Auflage 2012. Thieme-Verlag (Stuttgart)
15. Frohn C: Wann kann ich meine Rhesus-D-negative Patientin oder meinen Rhesus- D-negativen Patienten mit D-positiven Erythrozytenkonzentraten versorgen? Hämotherapie 27/2016: 42-46.

„Entdecke die Möglichkeiten“ Dauer der Antikoagulation nach venöser Thromboembolie Umgang mit Leitlinienempfehlungen in der Praxis

1. Interdisziplinäre S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Fassung vom 01.09.2015. AMWF online.
2. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores CL. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest 2016;149:315-352.
3. Interdisziplinäre S2-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Fassung vom 01.06.2010. AMWF online.
4. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-318.
5. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010;153:523-531.
6. Palareti G, Cosmi B, Legnani C, Antonucci E, De M, Ghirarduzzi VA, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014;124:196-203.
7. Kyrle PA & Eichinger S. Clincal scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012;108:1061-1064.
8. Mearns ES, Coleman CI, Patel D, Saulsberry WJ, Corman A, Li D, Hernandez AV, Kohn CG., Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. J Thromb Haemost 2015;13:1043-1052.
9. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le GG, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost 2014;111:172-179.
10. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, Kyrle P, Poli D, Tait RC, Iorio A. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011;342:d813.
11. Bueller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-1297.
12. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-718.
13. Agnelli G, Bueller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708.
14. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-1967.
15. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979-1987.
16. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Eng J Med 2017:376:1211-1222.

Checkliste für die Transfusion von Blutkomponenten

1. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz – TFG) Neufassung 28. August 2007.
2. Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie). Aufgestellt gemäß §§ 12a und 18 Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut. Gesamtnovelle 2017
3. Walther-Wenke, G., Zeiler, T. Das Blutdepot in der Einrichtung der Krankenversorgung; Struktur- Prozess- und Ergebnisqualität. hämotherapie 2016; 26:10-18.
4. Incorrect Blood Components Transfused (IBCT): Laboratory an Clinical Errors (mixed errors). SHOT REPORT 2015: 41-54.
5. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2015: 1-2,24-27.

Die maschinelle Autotransfusion

1. Spahn, D.R. and L.T. Goodnough, Alternatives to blood transfusion. Lancet, 2013. 381(9880): p. 1855-65.
2. Meybohm, P., et al., Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore), 2016. 95(31): p. e4490.
3. Vorstand der Bundesärztekammer auf Empfehlung des Wissenschaftlichen Beirats, Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. 2014. 4. überarbeitete Auflage.
4. Meybohm, P., et al., Patient Blood Mangement Maßnahmenbündel. Anästh Intensivmed, 2017. 58: p. 1-14.
5. Hansen, E., Leser fragen – Experten antworten – Maschinelle Autotransfusion. Anästhesiol Intensivmed Notfallmed Schmerzther, 2014. 49(05): p. 308-309.
6. Hansen, E. and T. Seyfried, [Cell salvage]. Anaesthesist, 2011. 60(4): p. 381-9; quiz 390.
7. Esper, S.A. and J.H. Waters, Intra-operative cell salvage: a fresh look at the indications and contraindications. Blood Transfus, 2011. 9(2): p. 139-47.
8. Seyfried, T.F., et al., Fat removal during cell salvage: a comparison of four different cell salvage devices. Transfusion, 2015. 55(7): p. 1637-43.
9. Seyfried, T.F., et al., Fat removal during cell salvage: an optimized program for a discontinuous autotransfusion device. Transfusion, 2016. 56(1): p. 153-159.
10. Ashworth, A. and A.A. Klein, Cell salvage as part of a blood conservation strategy in anaesthesia. BJA: British Journal of Anaesthesia, 2010. 105(4): p. 401-416.
11. Vorstand der Bundesärztekammer auf Empfehlung des Wissenschaftlichen Beirats, Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinien Hämotherapie) - Gesamtnovelle. 2017.
12. Takagi, H., et al., Intraoperative autotransfusion in abdominal aortic aneurysm surgery: Meta-analysis of randomized controlled trials. Archives of Surgery, 2007. 142(11): p. 1098-1101.
13. Shenolikar, A., et al., Cell salvage auto transfusion in total knee replacement surgery. Transfusion Medicine, 1997. 7(4): p. 277-280.
14. Kozek-Langenecker, S.A., et al., Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol, 2017. 34(6): p. 332-395.
15. Acheson, A.G., M.J. Brookes, and D.R. Spahn, Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg, 2012. 256(2): p. 235-44.
16. Hansen, E., Wundblutbestrahlung zur Retransfusion im Rahmen onkologischer Eingriffe. Der Onkologe, 2001. 7(3): p. 333-337.
17. Erlaubnisfreie Gewinnung und Anwendung von Blut im Rahmen der maschinellen Autotransfusion (MAT). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2014. 57(5): p. 595.
18. Kumar, N., et al., Use of intraoperative cell-salvage for autologous blood transfusions in metastatic spine tumour surgery: a systematic review. Lancet Oncol, 2014. 15(1): p. e33-41.
19. Goucher, H., et al., Cell Salvage in Obstetrics. Anesth Analg, 2015. 121(2): p. 465-8.
20. Milne, M.E., M.H. Yazer, and J.H. Waters, Red blood cell salvage during obstetric hemorrhage. Obstet Gynecol, 2015. 125(4): p. 919-23.
21. Fong, J., et al., An analysis of transfusion practice and the role of intraoperative red blood cell salvage during cesarean delivery. Anesth Analg, 2007. 104(3): p. 666-72.
22. Lemke, M., et al., A decision model and cost analysis of intra-operative cell salvage during hepatic resection. HPB (Oxford), 2016. 18(5): p. 428-35.
23. Oliveira, J.A.A., et al., Is cell salvage cost-effective in posterior arthrodesis for adolescent idiopathic scoliosis in the public health system? Journal of Spine Surgery, 2017. 3(1): p. 2-8.
24. Waters, J.H., et al., The volume of returned red blood cells in a large blood salvage program: where does it all go? (CME). Transfusion, 2011. 51(10): p. 2126-2132.

Indikationen zur Gabe von Blutprodukten in der Palliativmedizin (und in der Intensivmedizin)

1. Alt-Epping B., Simon A., Nauck F.: Substitution von Blutkomponenten in der Palliativversorgung. Dtsch Med. Wochenschr. 135: 2083-2087 (2010)
2. Asch D.A., Faber-Langendoen K., Shea J.A. et al.: The Sequence of Withdrawing Life-Sustaining Treatment from Patients. Am J Med 107 (2): 153-156 (1999)
3. Bleuler E.: Das autistisch-undisziplinierte Denken in der Medizin und seine Überwindung. Fünfter Neudruck der V. Auflage (Springer Verlag, Berlin) Neuausgabe von 1962 (1921)
4. Bundesärztekammer, Vorstand und wiss. Beirat (Hrsg.): Querschnittsleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Deutscher Ärzte-Verlag (2009) - www.baek.de/haemotherapie
5. Carson J.L., Terrin M.L., Noveck H. et al.: Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 365: 2453-2462 (2011)
6. Carson J.L., Sieber F., Cook D.R. et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 385: 1183-1189 (2015)
7. Goksu S.S., Gunduz S., Unal D. et al.: Use of Blood Transfusion at the End of Life: Does it Have Any Effects on Survival of Cancer Patients? Asian Pac J Cancer Prev 15 (10) 4251-4254 (2014)
8. Hebert P.C., Wells G., Hutchison J.S. et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409-417 (1999)
9. Hinkka H., Kosunen E., Metsänoja R., et al.: Factors affecting physicians‘ decisions to forgo life-sustaining treatments in terminal care. J Med Ethics 28:109-114 (2002)
10. Hinshaw D.B., Pawlik T., Mosenthal A.C. et al.: When Do We Stop, and How Do We Do It? Medical Futility and Withdrawal of Care. Am College of Surgeons, doi:10.1016/S1072-7515(03)00106-6 (2003)
11. Hopewell S., Omar O., Hyde Ch. et al.: A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open, doi:10.1136/bmjopen-2012-002154 (2013)
12. Leitlinienprogramm Onkologie Evidenztabellen. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung. AWMF-Reg_Nr.: 128/001OL – http://Leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html (Zugriff am: 16.07.2017) (Mai 2015)
13. Marik P.E., Corwin H.L.: Efficacy of red cell transfusion in the critical ill: a systematic review of the literature. Crit Care Med 36: 2667-2674 (2008)
14. Perel P., Clayton T., Altman D.G. et al.: Red Blood Cell Transfusion and Mortality in Trauma Patients: Risk-Stratified Analysis of an Observational Study. PLOS Med 11(6): e1001664. doi:10.1371/journal.pmed.1001664 (2014)
15. Rioux-Massé B., Laroche V., Bowman R.J. et al.: The influence of bleeding on trigger changes for platelet transfusion in patients with chemotherapy-induced thrombocytopenia. TRANSFUSION 53: 306-314 (2013)
16. Slichter S.J.: Eliminate Prophylactic Platelet Trabsfusions? N Engl J Med 368: 1837-1838 (2013)
17. Smith B.L., Cooling L., and Davenport R.: How do I allocate blood products at the end of Life? An ethical analysis with suggested guidelines. TRANSFUSION 53: 696-700 (2013)
18. Stanworth S.J., Estcourt L.J., Chir B. et al.: A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. N Engl J Med 368: 1771-1780 (2013)
19. Thiele Th., Krüger W., Zimmermann K. et al.: Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. TRANSFUSION 51: 2620-2626 (2011)
20. Vamvacas E.C., Blajchman M.A.: Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 21: 327-348 (2007)
21. Walsh T.S., Boyd J.A., Watson D. et al.: Restrictive Versus Liberal Transfusion Strategies for Older Mechanical Ventilated Critical Ill Patients: A Randomized Pilot Trial. Crit Care Med 41: 2354-2363 (2013)
22. Wandt H., Schaefer-Eckart K., Wendelin K. et al.: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380: 1309-1316 (2012)
23. Wang T., Luo L., Huang H. et al.: Perioperative Blood Transfusion Is Assozciated With Worse Clinical Outcomes in Resected Lung Cancer. Ann Thorac Surg 97: 1827-1837 (2014)
24. Williamson L.M., Stainsby D., Jones H. et al.: The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. TRANSFUSION 47: 1455-1467 (2007)

Indikationen zur Gabe von Blutprodukten in der Palliativmedizin (und in der Intensivmedizin)

1. Alt-Epping B., Simon A., Nauck F.: Substitution von Blutkomponenten in der Palliativversorgung. Dtsch Med. Wochenschr. 135: 2083-2087 (2010)
2. Asch D.A., Faber-Langendoen K., Shea J.A. et al.: The Sequence of Withdrawing Life-Sustaining Treatment from Patients. Am J Med 107 (2): 153-156 (1999)
3. Bleuler E.: Das autistisch-undisziplinierte Denken in der Medizin und seine Überwindung. Fünfter Neudruck der V. Auflage (Springer Verlag, Berlin) Neuausgabe von 1962 (1921)
4. Bundesärztekammer, Vorstand und wiss. Beirat (Hrsg.): Querschnittsleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Deutscher Ärzte-Verlag (2009) - www.baek.de/haemotherapie
5. Carson J.L., Terrin M.L., Noveck H. et al.: Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 365: 2453-2462 (2011)
6. Carson J.L., Sieber F., Cook D.R. et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 385: 1183-1189 (2015)
7. Goksu S.S., Gunduz S., Unal D. et al.: Use of Blood Transfusion at the End of Life: Does it Have Any Effects on Survival of Cancer Patients? Asian Pac J Cancer Prev 15 (10) 4251-4254 (2014)
8. Hebert P.C., Wells G., Hutchison J.S. et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409-417 (1999)
9. Hinkka H., Kosunen E., Metsänoja R., et al.: Factors affecting physicians‘ decisions to forgo life-sustaining treatments in terminal care. J Med Ethics 28:109-114 (2002)
10. Hinshaw D.B., Pawlik T., Mosenthal A.C. et al.: When Do We Stop, and How Do We Do It? Medical Futility and Withdrawal of Care. Am College of Surgeons, doi:10.1016/S1072-7515(03)00106-6 (2003)
11. Hopewell S., Omar O., Hyde Ch. et al.: A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open, doi:10.1136/bmjopen-2012-002154 (2013)
12. Leitlinienprogramm Onkologie Evidenztabellen. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung. AWMF-Reg_Nr.: 128/001OL – http://Leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html (Zugriff am: 16.07.2017) (Mai 2015)
13. Marik P.E., Corwin H.L.: Efficacy of red cell transfusion in the critical ill: a systematic review of the literature. Crit Care Med 36: 2667-2674 (2008)
14. Perel P., Clayton T., Altman D.G. et al.: Red Blood Cell Transfusion and Mortality in Trauma Patients: Risk-Stratified Analysis of an Observational Study. PLOS Med 11(6): e1001664. doi:10.1371/journal.pmed.1001664 (2014)
15. Rioux-Massé B., Laroche V., Bowman R.J. et al.: The influence of bleeding on trigger changes for platelet transfusion in patients with chemotherapy-induced thrombocytopenia. TRANSFUSION 53: 306-314 (2013)
16. Slichter S.J.: Eliminate Prophylactic Platelet Trabsfusions? N Engl J Med 368: 1837-1838 (2013)
17. Smith B.L., Cooling L., and Davenport R.: How do I allocate blood products at the end of Life? An ethical analysis with suggested guidelines. TRANSFUSION 53: 696-700 (2013)
18. Stanworth S.J., Estcourt L.J., Chir B. et al.: A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. N Engl J Med 368: 1771-1780 (2013)
19. Thiele Th., Krüger W., Zimmermann K. et al.: Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. TRANSFUSION 51: 2620-2626 (2011)
20. Vamvacas E.C., Blajchman M.A.: Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 21: 327-348 (2007)
21. Walsh T.S., Boyd J.A., Watson D. et al.: Restrictive Versus Liberal Transfusion Strategies for Older Mechanical Ventilated Critical Ill Patients: A Randomized Pilot Trial. Crit Care Med 41: 2354-2363 (2013)
22. Wandt H., Schaefer-Eckart K., Wendelin K. et al.: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380: 1309-1316 (2012)
23. Wang T., Luo L., Huang H. et al.: Perioperative Blood Transfusion Is Assozciated With Worse Clinical Outcomes in Resected Lung Cancer. Ann Thorac Surg 97: 1827-1837 (2014)
24. Williamson L.M., Stainsby D., Jones H. et al.: The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. TRANSFUSION 47: 1455-1467 (2007)